t
Tissue Regenix Group plc announced on 18 March 2025 an update regarding its ongoing review of strategic options. As a consequence, the Company's Final Results for the year ended 31 December 2024 will be announced later than in prior years, with a specific results date to be announced in due course.
| Date | 18 Mar 2025 |
| Time | 07:00:02 |
| Category | Corporate updates |
| ID | 9901A |
Tissue Regenix Group plc
('Tissue Regenix', the 'Group' or the 'Company')
Company update
Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that further to the announcement made on 30 January 2025, the Company continues to execute on its 4S strategy and trading remains in line with the Board's expectations, as the Group looks to drive further growth in 2025.
The Company's review of strategic options is ongoing and as a consequence of this, it is expected that the Final Results for the year ended 31 December 2024 will be announced later than in prior years, and a results date and an update on the review of strategic options will be announced in due course.
For more information, please contact:
|
Tissue Regenix Group plc |
|
|
|
Daniel Lee, Chief Executive Officer
|
via Walbrook PR |
|
|
David Cocke, Chief Financial Officer |
|
|
|
|
|
|
|
Cavendish Capital Markets (Nominated Adviser and Broker) |
Tel: +44 (0) 20 7466 5000 |
|
|
Geoff Nash/Giles Balleny/Edward Whiley |
|
|
|
Nigel Birks - Life Science Specialist Sales |
|
|
|
Harriet Ward - ECM |
|
|
|
|
|
|
|
Walbrook PR (Financial PR and IR) |
Tel: +44 (0)20 7933 8780 |
|
|
Alice Woodings / Lianne Applegarth |
||
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.